

### **Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application.

### **Listing of Claims**

1-32. (Cancelled)

33. (Currently Amended) A process for inducing a neutralizing antibody response in a subject against HIV comprising administering an immunogenic composition directly to mucous membranes, wherein the immunogenic composition comprises:

(a) an antigen that comprises a C-terminal truncated gp160 protein, wherein the C-terminal truncated gp160 protein has a molecular mass of about 140 kDa and ~~consists essentially of the sequence set forth at residues 33-681 of SEQ ID NO:1~~ comprises the endogenous hydrophobic amino acid sequence set forth at positions 523-551 of SEQ ID NO:1;

(b) proteosomes, wherein the proteosomes are complexed or coupled with the antigen; and

(c) bioadhesive nanoemulsions,

wherein the immunogenic composition elicits neutralizing antibodies to HIV in a subject upon administration of the immunogenic composition to the subject, and wherein the neutralizing antibodies are present in one or more of vaginal secretions, intestinal secretions, lung secretions, and feces.

34. (Previously Presented) The process according to claim 33 wherein the immunogenic composition is administered by an intranasal or respiratory route.

35. – 37. (Canceled)

38. (Previously Presented) The process according to claim 33 wherein the C-terminal truncated gp160 protein is an oligomeric C-terminal truncated gp160 from HIV-1.

39. (Previously Presented) The process according to claim 33 wherein the C-terminal truncated gp160 protein is recombinantly produced.

40. – 42. (Canceled)